LOTUS: Investigation of Ipatasertib, a Novel Akt Inhibitor, in Combination With Paclitaxel as Frontline Therapy for Metastatic TNBC

Slideset - The addition of ipatasertib to paclitaxel improved PFS for patients with metastatic TNBC, with the greatest benefit observed in a prespecified subgroup analysis of patients withPIK3CA/AKT1/PTEN-altered tumors.
Source: Clinical Care Options Breast Cancer - Category: Cancer & Oncology Source Type: research